We are developing a novel class of antimicrobial peptides, based on a linear amphipathic β-sheet motif, that possesses high antimicrobial potency combined with low mammalian cell toxicity.  These peptides bind to and induce lysis in target membranes.

 We are testing these peptides as potential topical agents for methicillin-resistant S. aureus (MRSA) and S. epidermidis nosocomial infections and for antiviral activity.